3D-AttenNet model can predict clinically significant prostate cancer in PI-RADS category 3 patients: a retrospective multicenter study
Open Access
- 29 January 2025
- journal article
- research article
- Published by Springer Nature in Insights into Imaging
- Vol. 16 (1) , 1-13
Abstract
Purposes: The presence of clinically significant prostate cancer (csPCa) is equivocal for patients with prostate imaging reporting and data system (PI-RADS) category 3. We aim to develop deep learning models for re-stratify risks in PI-RADS category 3 patients. Methods: This retrospective study included a bi-parametric MRI of 1567 consecutive male patients from six centers (Centers 1–6) between Jan 2015 and Dec 2020. Deep learning models with double channel attention modules based on MRI (AttenNet) for predicting PCa and csPCa were constructed separately. Each model was first pretrained using 1144 PI-RADS 1–2 and 4–5 images and then retrained using 238 PI-RADS 3 images from three training centers (centers 1–3), and tested using 185 PI-RADS 3 images from the other three testing centers (centers 4–6). Results: Our AttenNet models achieved excellent prediction performances in testing cohort of center 4–6 with the area under the receiver operating characteristic curves (AUC) of 0.795 (95% CI: [0.700, 0.891]), 0.963 (95% CI: [0.915, 1]) and 0.922 (95% CI: [0.810, 1]) in predicting PCa, and the corresponding AUCs were 0.827 (95% CI: [0.703, 0.952]) and 0.926 (95% CI: [0.846, 1]) in predicting csPCa in testing cohort of center 4 and center 5. In particular, 71.1% to 92.2% of non-csPCa patients were identified by our model in three testing cohorts, who can spare from invasive biopsy or RP procedure. Conclusions: Our model offers a noninvasive screening clinical tool to re-stratify risks in PI-RADS 3 patients, thereby reducing unnecessary invasive biopsies and improving the effectiveness of biopsies. Critical relevance statement: The deep learning model with MRI can help to screen out csPCa in PI-RADS category 3. Key Points: AttenNet models included channel attention and soft attention modules. 71.1–92.2% of non-csPCa patients were identified by the AttenNet model. The AttenNet models can be a screen clinical tool to re-stratify risks in PI-RADS 3 patients. GraphicalKeywords
Funding Information
- National Natural Science Foundation of China (82402227)
- Natural Science Foundation of Beijing Municipality (Z200027)
- the Suzhou Science and Technology Development Plan Project (KJXW2023006)
This publication has 30 references indexed in Scilit:
- Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRIEuropean Radiology, 2022
- Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosisAbdominal Radiology, 2021
- Magnetic Resonance Imaging Radiomics‐Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI‐RADS 3 LesionsJournal of Magnetic Resonance Imaging, 2021
- A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesionsAbdominal Radiology, 2020
- Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysisEuropean Urology, 2020
- Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2European Urology, 2019
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2European Urology, 2016
- Contemporary Prostate Cancer Prevalence among T1c Biopsy-Referred Men with a Prostate-Specific Antigen Level ≤ 4.0ng per MilliliterEuropean Urology, 2008